[1] Rajkumar SV.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management[J]. Am J Hematol,2016,91(7):719-734.
[2] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin,2017,67(1):7-30.
[3] Huang SY, Yao M, Tang JL, et al.Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years[J]. Cancer,2007,110(4):896-905.
[4] Kang SH, Kim TY, Kim HY, et al.Protective role of CYP1A1*2A in the development of multiple myeloma[J]. Acta Haematol,2008,119(1):60-64.
[5] Kim K, Lee JH, Kim JS, et al.Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study[J]. Am J Hematol,2014,89(7):751-756.
[6] Lee JH, Lee DS, Lee JJ, et al.Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party[J]. Int J Hematol,2010,92(1):52-57.
[7] Lu J, Lee JH, Huang SY, et al.Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial[J]. Br J Haematol,2017,176(5):743-749.
[8] Greenberg AJ, Rajkumar SV, Therneau TM, et al.Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma[J]. Leuk-emia,2014,28(2):398-403.
[9] Avet-Loiseau H.Role of genetics in prognostication in myeloma[J]. Best Pract Res Clin Haematol,2007,20(4):625-635.
[10] Weinhold N, Heuck CJ, Rosenthal A, et al.Clinical value of molecular subtyping multiple myeloma using gene expression profiling[J]. Leukemia,2016,30(2):423-430.
[11] National Comprehensive Cancer Network. Muliple Myeloma[R/OL]. 2016[2017-09-20]http://www.nccn.org/patients.
[12] Kaushansky主编,陈竺译. 威廉姆斯血液学[M]. 8版.人民卫生出版社,2011:11.
[13] An G, Xu Y, Shi L, et al.t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome[J]. Leuk Res,2013,37(10):1251-1257.
[14] Robillard N, Avet-Loiseau H, Garand R et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma[J]. Blood,2003,102(3):1070-1071.
[15] Caleb KS, Faith ED, Christoph H, et al.Molecular subtyping and risk stratification for the classification of myeloma[J]. J Auton Nerv Syst,2015,48(1):17-29.
[16] Avet-Loiseau H, Durie BG, Cavo M, et al.Combining fluo-rescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project[J]. Leukemia,2013,27(3):711-717.
[17] Mikhael JR, Dingli D, Roy V, et al.Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013[J]. Mayo Clin Proc,2013,88(4):360-376.
[18] Sergentanis TN, Kastritis E, Terpos E, et al.Cytogenetics and survival of multiple myeloma: Isolated and combined effects[J]. Clin Lymphoma Myeloma Leuk,2016,16(6):335-340.
[19] Avet-Loiseau H, Leleu X, Roussel M, et al.Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)[J]. J Clin Oncol,2010,28(30):4630-4634.
[20] Sonneveld P, Avet-Loiseau H, Lonial S, et al.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group[J]. Blood,2016,127(24):2955-2962.
[21] Yu W, Guo R, Qu X, et al.The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population[J]. Onco Targets Ther,2016,9:295-302.
[22] Grzasko N, Hus M, Pluta A, et al.Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients[J]. Hematol Oncol,2013,31(1):41-48.
[23] Shaughnessy JD Jr, Zhan F, Burington BE, et al.A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1[J]. Blood,2007,109(6):2276-2284.
[24] Weinhold N, Heuck CJ, Rosenthal A, et al.Clinical value of molecular subtyping multiple myeloma using gene expression profiling[J]. Leukemia,2016,30(2):423-430.
[25] Palumbo A, Avet-Loiseau H, Oliva S, et al.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group[J]. J Clin Oncol,2015,33(26):2863-2869.
[26] Mikkilineni L, Kochenderfer JN. Chimeric Antigen Receptor T-cell Therapies for Multiple Myeloma[J]. Blood,2017,pii: blood-2017-06-793869.
